Janeva, Martina and Gjorgieva Ackova, Darinka (2018) IL-6: important cytokine in state of health and disease. In: Prv kongres na studenti po Opsta medicina, 9-10 May 2018, Faculty of Medical Sciences, University Goce Delcev Stip.
Preview |
Text
IL-6-martina-janeva-abstract.pdf Download (165kB) | Preview |
Preview |
Text
Poster-Kongres OM-2018.pdf Download (877kB) | Preview |
![[thumbnail of slika 1.png]](/21241/3/slika%201.png)  Preview |
Image
slika 1.png Download (724kB) | Preview |
![[thumbnail of slika 2.png]](/21241/4/slika%202.png)  Preview |
Image
slika 2.png Download (615kB) | Preview |
![[thumbnail of slika 3.png]](/21241/5/slika%203.png)  Preview |
Image
slika 3.png Download (616kB) | Preview |
![[thumbnail of slika 4.png]](/21241/6/slika%204.png)  Preview |
Image
slika 4.png Download (606kB) | Preview |
![[thumbnail of slika 5.png]](/21241/7/slika%205.png)  Preview |
Image
slika 5.png Download (735kB) | Preview |
![[thumbnail of slika 6.png]](/21241/8/slika%206.png)  Preview |
Image
slika 6.png Download (682kB) | Preview |
![[thumbnail of slika 7.png]](/21241/9/slika%207.png)  Preview |
Image
slika 7.png Download (130kB) | Preview |
Abstract
Interleukin-6 (IL-6) is a pleiotropic cytokine with significant functions in the regulation of the immune system. Since its discovery in 1986, originally as B cell stimulating factor 2, the knowledge and interest on IL-6 as a potent pro-inflammatory cytokine important for immune homeostasis, innate and adaptive immunity to viral, parasitic and bacterial infection and its pathophysiological implications in the pathogenesis of various human diseases as inflammation, autoimmunity and cancer, has rapidly increased. However, the causes of disregulated IL-6 production still remain unknown.
In this work we analyzed published studies concerning IL-6 and evaluated data from pre-clinical and clinical trials in the attempt to explain the synthesis, actions, and possibilities for therapy where IL-6 will be included.
To this moment, anti-IL-6 therapies have been developed for the treatment of autoimmune diseases (as rheumatoid arthritis) and in cancers including approved monoclonal antibodies against IL-6 (siltuximab) or IL-6 receptor (tocilizumab), while other inhibitors are at the stage of clinical trials.
IL-6 with whole complexicity of its nature is a delicate target for therapeutic interventions and complex future researches are needed to use its potential for improving disease outcome.
| Item Type: | Conference or Workshop Item (Poster) |
|---|---|
| Subjects: | Medical and Health Sciences > Basic medicine Medical and Health Sciences > Other medical sciences |
| Divisions: | Faculty of Medical Science |
| Depositing User: | Darinka Gorgieva Ackova |
| Date Deposited: | 01 Feb 2019 10:08 |
| Last Modified: | 01 Feb 2019 10:08 |
| URI: | https://eprints.ugd.edu.mk/id/eprint/21241 |
Actions (login required)
 |
View Item |